KR20230013077A - 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 - Google Patents

코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 Download PDF

Info

Publication number
KR20230013077A
KR20230013077A KR1020227044294A KR20227044294A KR20230013077A KR 20230013077 A KR20230013077 A KR 20230013077A KR 1020227044294 A KR1020227044294 A KR 1020227044294A KR 20227044294 A KR20227044294 A KR 20227044294A KR 20230013077 A KR20230013077 A KR 20230013077A
Authority
KR
South Korea
Prior art keywords
cov
sars
mek inhibitor
atr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044294A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 루드비히
올리버 플란츠
헬렌 엘리자 호프만
율리아 코흐-하이어
미카엘 쉰들러
Original Assignee
아트리바 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트리바 테라퓨틱스 게엠베하 filed Critical 아트리바 테라퓨틱스 게엠베하
Publication of KR20230013077A publication Critical patent/KR20230013077A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227044294A 2020-05-20 2021-05-20 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 Pending KR20230013077A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175739.0 2020-05-20
EP20175739.0A EP3912623B1 (en) 2020-05-20 2020-05-20 Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (1)

Publication Number Publication Date
KR20230013077A true KR20230013077A (ko) 2023-01-26

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044294A Pending KR20230013077A (ko) 2020-05-20 2021-05-20 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제

Country Status (11)

Country Link
US (1) US20230241014A1 (https=)
EP (2) EP3912623B1 (https=)
JP (1) JP2023526836A (https=)
KR (1) KR20230013077A (https=)
CN (1) CN116635022A (https=)
AU (1) AU2021277517A1 (https=)
BR (1) BR112022023013A2 (https=)
CA (1) CA3178137A1 (https=)
ES (1) ES2995196T3 (https=)
MX (1) MX2022014561A (https=)
WO (1) WO2021234097A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
US20240165099A1 (en) * 2022-09-30 2024-05-23 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420778B1 (en) * 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections

Also Published As

Publication number Publication date
US20230241014A1 (en) 2023-08-03
BR112022023013A2 (pt) 2022-12-20
AU2021277517A1 (en) 2022-12-08
ES2995196T3 (en) 2025-02-07
EP3912623A1 (en) 2021-11-24
CA3178137A1 (en) 2021-11-25
CN116635022A (zh) 2023-08-22
EP4153159A1 (en) 2023-03-29
EP3912623B1 (en) 2024-07-31
JP2023526836A (ja) 2023-06-23
EP3912623C0 (en) 2024-07-31
WO2021234097A1 (en) 2021-11-25
MX2022014561A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
KR20230013077A (ko) 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제
Severa et al. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
Ivanciuc et al. Hydrogen sulfide is an antiviral and antiinflammatory endogenous gasotransmitter in the airways. Role in respiratory syncytial virus infection
Kelley et al. Cellular senescence: friend or foe to respiratory viral infections?
De-Simone et al. IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression
Qin et al. Baicalin induces a potent innate immune response to inhibit respiratory syncytial virus replication via regulating viral non-structural 1 and matrix RNA
EP4146192A1 (en) Methods and compositions for the treatment of sars-cov-2
Yuan et al. Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters
Marim et al. Inhibition of tryptophan catabolism is associated with neuroprotection during zika virus infection
Bello-Perez et al. MERS-CoV ORF4b is a virulence factor involved in the inflammatory pathology induced in the lungs of mice
Bai et al. Cyclosporine A regulates influenza A virus-induced macrophages polarization and inflammatory responses by targeting cyclophilin A
US20230233483A1 (en) Compound and method for the treatment of coronaviruses
Wang et al. Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection in vitro
Du et al. Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19
EP4186500A1 (en) Mek inhibitors for the prevention and treatment of long covid syndrome
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
Belouzard et al. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
Bravo-Silva et al. Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections
Kerr et al. IFN-γ signaling is required for the efficient replication of murine hepatitis virus (MHV) strain JHM in the brains of infected mice
Kumar et al. Mucosal implications of oral Jak3-targeted drugs in COVID patients
Guayasamin et al. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector
Baek et al. Parental Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Predominates Over Coinfected SARS‐CoV‐2 Delta, Producing Less Lethal Variants in a Long‐Term Replication Mouse Model
US20220323402A1 (en) Treatment, amelioration or prevention of a viral infection
KR102602043B1 (ko) 프랄라트렉세이트(Pralatrexate)를 유효성분으로 포함하는 항바이러스 조성물
US20180369302A1 (en) Epizootic hemorrhagic disease virus - tel aviv university (ehdv-tau) - oncolytic virus for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240517

Comment text: Request for Examination of Application